Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trialsG. Ferretti, Paolo Carlini, Carmen Nuzzo et al.|British Journal of Cancer|2006Cited by 38
Aromatase inhibitors in post-menopausal metastatic breast carcinomaPaolo Carlini, G. Ferretti, Emilio Bria et al.|Expert Opinion on Investigational Drugs|2007Cited by 5
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective studyÉlisa Gobbini, Silvia Novello, Rita Chiari et al.|Clinical & Translational Oncology|2019Cited by 5
Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?Alessandra Fabi, F. Cognetti, G. Ferretti et al.|Annals of Oncology|2005Cited by 4
Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?Paola Papaldo, Francesco Cognetti, Serena Di Cosimo et al.|The Breast|2005Cited by 2